Role of phenothiazines and structurally similar compounds of plant origin in the fight against infections by drug resistant bacteria

Antibiotics

Volumn 2, Issue 1, 2013, Pages 58-72

  Dastidar, Sujata G ^a   Kristiansen, Jette E ^b   Molnar, Joseph ^c   Amaral, Leonard ^c,d  

^a Herbicure Healthcare Bio Herbal Research Foundation   (India)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SZEGED   (Hungary)

^d INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

Antimicrobial activities; Efflux pumps; Phenothiazines; Quorum sensing; Reversal of antibiotic resistance

Indexed keywords

ALIMEMAZINE; CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE; METHDILAZINE; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; PROMAZINE; PROMETHAZINE; THIORIDAZINE; TRIFLUOPERAZINE; TRIFLUPROMAZINE;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CELL MEMBRANE TRANSPORT; DRUG POTENTIATION; DRUG RESPONSE; EXTRACTION AND EXTRACTS; HUMAN; MEDICINAL PLANT; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW;

BACTERIA (MICROORGANISMS); EUKARYOTA; PROKARYOTA;

EID: 84887610539     PISSN: None     EISSN: 20796382     Source Type: Journal    
DOI: 10.3390/antibiotics2010058     Document Type: Review

References (81)

1. Falagas, M. E.; Bliziotis, I. A. Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era. Int. J. Antimicrob. Agents 2007, 29, 630-636.
2. Amaral, L.; Udwadia, Z. F.; van Soolingen, D. A cheap and effective anti-Mdr/Xdr/Tdr Tb drug is already available. Biochem. Pharmacol. J. 2012, doi: 10. 4172/2167-0501. 1000e137.
3. Amaral, L.; Molnar, J. Why and how the old neuroleptic thioridazine cures the XDR-TB patient. Pharmaceuticals 2012, 5, 1021-1031.
4. Amaral, L.; Udwadia, Z.; Abbate, E.; van Soolingen, D. The added effect of Thioridazine in treatment of resistant TB. Int. J. Tuberc. Lung Dis. 2012, 16, 1706-1708.
5. Chopra, I.; Schofield, C.; Everett, M.; O'Neill, A.; Miller, K.; Wilcox, M.; Frère, J.-M.; Dawson, M.; Czaplewski, L.; Urleb, U.; et al. Treatment of health-careassociated infections caused by Gram-negative bacteria: A consensus statement. Lancet Infect. Dis. 2008, 8, 133-139.
6. Kristiansen, J. E. The antimicrobial activity of non-antibiotics. Report from a congress on the antimicrobial effect of drugs other than antibiotics on bacteria, viruses, protozoa, and other organisms. APMIS. Suppl. 1992, 30, 7-14.
7. Guttmann, P.; Ehrlich, P. Ueber die wirkung des methylenblau bei malaria. Berliner Klinische Wochenschrift 1891, 39, 953-956.
8. Kristiansen, J. E.; Amaral, L. The potential management of resistant infections with non-antibiotics. J. Antimicrob. Chemother. 1997, 40, 319-327.
9. Dastidar, S. G.; Saha, P. K.; Sanyamat, B.; Chakrabarty, A. N. Antibacterial activities of ambodryl and benadryl. J. Appl. Bact. 1976, 41, 209-214.
10. Annadurai, S.; Basu, S.; Ray, S.; Dastidar, S. G.; Chakrabarty, A. N. Antimicrobial activity of the antiinflammatory agent diclofenac sodium. Indian J. Exp. Biol. 1998, 36, 86-90.
11. Kumar, K. A.; Ganguly, K.; Mazumdar, K.; Dutta, N. K.; Dastidar, S. G.; Chakrabarty, A. N. Amlodipine: A cardiovascular drug with powerful antimicrobial property. Acta Microbiol. Pol. 2003, 52, 285-292.
12. Mazumdar, K.; Ganguly, K.; Kumar, K. A.; Dutta, N. K.; Chakrabarty, A. N.; Dastidar, S. G. Antimicrobial potentiality of a new non-antibiotic: The cardiovascular drug oxyfedrine hydrochloride. Microbiol. Res. 2003, 158, 259-264.
13. Dasgupta, A.; Dastidar, S. G.; Shiratki, Y.; Motohashi, N. Antibacterial Activity of Artificial Phenothiazines and Isoflavones from Plants. In Bioactive Heterocycles VI; Springer: Berlin/Heidelberg, Germany, 2008; Volume 15, pp. 67-132.
14. Kristiansen, J. E. Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall. Acta Pathol. Microbiol. Scand. B 1979, 87, 317-319.
15. Galeazzi, L.; Turchetti, G.; Grilli, G.; Groppa, G.; Giunta, S. Chlorpromazine as permeabilizer and reagent for detection of microbial peroxidase and peroxidaselike activities. Appl. Environ. Microbiol. 1986, 52, 1433-1435.
16. Amaral, L.; Lorian, V. Effects of chlorpromazine on the cell envelope proteins of Echerichia coli. Antimicrob. Agents Chemother. 1991, 35, 1923-1924.
17. Amaral, L.; Kristiansen, J. E.; Thomsen, V. F.; Markowich, B. The effect of chlorpromazine on the outer cell wall constituents of Salmonella typhimurium ensuring resistance to the drug. Int. J. Antimicrob. Agents 2000, 14, 225-229.
18. Radhakrishnan, V.; Ganguly, K.; Ganguly, M.; Dastidar, S. G.; Chakrabarty, A. N. Potentiality of tricyclic compound thioridazine as an effective antibacterial and antiplasmid agent. Indian J. Exp. Biol. 1999, 37, 671-675.
19. Page, A. M.; Lagnado, J. R. Effects of phenothiazine neuroleptic drugs on the microtubular-membrane complex in bloodstream forms of Trypanosoma brucei. Parasitology 1995, 111, 493-504.
20. Bourlioux, P.; Moreaux, J. M.; Su, W. J.; Boureau, H. In vitro antimicrobial activity of 18 phenothiazine derivatives: Structure-activity relationship. APMIS Suppl. 1992, 30, 40-43.
21. Mitruka, B. M., Rawnsle, H. M., Vadehra, D. V., Eds. Animal of Medical Research; John Wiley & Sons, Inc.: NY, NY, USA, 1976; Volume 301, pp. 145-150.
22. Ordway, D.; Viveiros, M.; Leandro, C.; Arroz, M. J.; Amaral, L. Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents 2001, 20, 34-43.
23. Martins, M.; Dastidar, S. G.; Fanning, S.; Kristiansen, J. E.; Molnar, J.; Pagès, J. M.; Schelz, Z.; Spengler, G.; Viveiros, M.; Amaral, L. Potential role of non-antibiotics (helper compounds) in the treatment of multi-drug resistant Gram negative infections: Mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents 2008, 31, 198-208.
24. Dutta, N. K.; Mazumdar, K.; Dastidar, S. G.; Amaral, L. New Patentable use of an old neuroleptic compound thioridazine to combat against tuberculosis: Gene regulation perspective. Recent Pat. Anti-Infect. Drug Discov. 2011, 6, 128-138.
25. Spengler, G.; Rodrigues, L.; Martins, M.; McCusker, M.; Cerca, P.; Machado, L.; Costa, S. S.; Ntokoue, E.; Couto, I.; Viveiros, M.; et al. Genetic Response of Salmonella enterica serovar Typhimurium to Thioridazine rendering the organism resistant to the agent. Int. J. Antimicrob. Agents 2012, 39, 16-21.
26. Dastidar, S. G.; Mahapatra, S. K.; Ganguly, K.; Chakrabarty, A. N. Antimicrobial activity of prenylflavanones. In Vivo 2001, 15, 519-524.
27. Dastidar, S. G.; Manna, A.; Kumar, K. A.; Mazumdar, K.; Dutta, N. K.; Chakrabarty, A. N.; Motohashi, N.; Shirataki, Y. Studies on the antibacterial potentiality of isoflavones. Int. J. Antimicrob. Agents 2004, 23, 99-102.
28. Mazumder, R.; Dastidar, S. G.; Basu, S. P.; Mazumder, A. Effect of Mesua ferrea Linn. flower extract on Salmonella. Indian J. Exp. Biol. 2005, 43, 566-568.
29. Ramalhete, C.; Spengler, G.; Mulhovo, S.; Costa, S.; Couto, I.; Viveiros, M.; Ferreira, M. J. U.; Amaral, L. Inhibition of efflux pumps of methicillin-resistant Staphylococcus aureus and Enterococcus faecalis resistant strains by triterpenoids from Momordica balsamina. Int. J. Antimicrob. Agents 2011, 77, 70-74.
30. Martins, A.; Vasas, A.; Viveiros, M.; Molnar, J.; Hohmann, J.; Amaral, L. Antibacterial properties of compounds isolated from Carpobrotus edulis. Int. J. Antimicrob. Agents 2011, 37, 438-444.
31. Ramalhete, C.; Spengler, G.; Serly, J.; Amaral, L.; Molnar, J.; Mulhovo, S.; Ferreira, M. J. U. Efflux modulators from Momordica balsamina L. in multidrug resistant bacterial strains. Planta Med. 2009, 75, 896-896.
32. Duarte, N.; Ferreira, M. J.; Martins, M.; Viveiros, M.; Amaral, L. Antibacterial activity of ergosterol peroxide against Mycobacterium tuberculosis: Dependence upon system and medium employed. Phytother. Res. 2007, 21, 601-604.
33. Lorenzi, V.; Muselli, A.; Bernardini, A. F.; Berti, L.; Pagès, J. M.; Amaral, L.; Bolla, J. M. Helichrysum italicum essential oil contains compounds that restore chloramphenicol activity on multi-drug resistant isolates from Gram-negative species. Antimicrob. Agents Chemother. 2008, 53, 2209-2211.
34. Wainwright, M.; Amaral, L.; Kristiansen, J. E. The Evolution of Antimycobacterial Agents from Non-Antibiotics. Open J. Pharmacol. 2012, 2, e1.
35. Pluta, K.; Morak-Młodawska, B.; Jeleń, M. Recent progress in biological activities of synthesized phenothiazines. Eur. J. Med. Chem. 2011, 46, 3179-3189.
36. Kristiansen, J. E.; Hendricks, O.; Delvin, T.; Butterworth, T. S.; Aagaard, L.; Christensen, J. B.; Flores, V. C.; Keyzer, H. Reversal of resistance in microorganisms by help of non-antibiotics. J. Antimicrob. Chemother. 2007, 59, 1271-1279.
37. Harris, F.; Chatfield, L. K.; Phoenix, D. A. Phenothiazinium based photosensitisers-photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr. Drug Targets 2005, 6, 615-627.
38. Lala, A. K. Fluorescent and photoactivable probes in depth-dependent analysis of membranes. Chem. Phys. Lipids 2002, 116, 177-188.
39. Michalak, K.; Wesolowska, O.; Motohashi, N.; Molnar, J.; Hendrich, A. B. Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Curr. Drug Targets 2006, 7, 1095-1105.
40. Cheeseman, H. J.; Neal, M. J. Interaction of chlorpromazine with tea and coffee. Br. J. Clin. Pharmacol. 1981, 12, 165-169.
41. Weiss, B.; Prozialeck, W.; Cimino, M.; Barnette, M. S.; Wallace, T. L. Pharmacological regulation of calmodulin. Ann. NY Acad. Sci. 1980, 356, 319-345.
42. Davidoff, R. A. Antispasticity drugs: Mechanisms of action. Ann. Neurol. 1985, 17, 107-116.
43. Amaral, L.; Spengler, G.; Martins, A.; Armada, A.; Handzlik, J.; Kiec-Kononowicz, K.; Molnar, J. Inhibitors of bacterial efflux pumps that also inhibit efflux pumps of cancer cells. Anticancer Res. 2012, 32, 2947-2957.
44. Vila, J.; Martínez, J. L. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors. Curr. Drug Targets 2008, 9, 797-807.
45. Pagès, J. M.; Amaral, L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta 2009, 1794, 826-833.
46. Amaral, L.; Fanning, S.; Pagès, J. M. Efflux pumps of gram-negative bacteria: Genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines. Adv. Enzymol. Relat. Areas Mol. Biol. 2011, 77, 61-108.
47. Spengler, G.; Molnar, J.; Viveiros, M.; Amaral, L. Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 andinhibits the expression of P-glycoprotein. Anticancer Res. 2011, 31, 4201-4205.
48. Spengler, G.; Handzlik, J.; Ocsovszki, I.; Viveiros, M.; Kiec-Kononowicz, K.; Molnar, J.; Amaral, L. Modulation of multidrug efflux pump activity by new hydantoin derivatives on colon adenocarcinoma cells without inducing apoptosis. Anticancer Res. 2011, 31, 3285-3288.
49. Viveiros, M.; Portugal, I.; Bettencourt, R.; Victor, T. C.; Jordaan, A. M.; Leandro, C.; Ordway, D.; Amaral, L. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2002, 46, 2804-2810.
50. Viveiros, M.; Jesus, A.; Brito, M.; Leandro, C.; Martins, M.; Ordway, D.; Molnar, A. M.; Molnar, J.; Amaral, L. Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and the expression of proton gradient dependent multidrug efflux pump genes. Antimicrob. Agents Chemother. 2005, 49, 3578-3582.
51. Martins, A.; Spengler, G.; Rodrigues, L.; Viveiros, M.; Ramos, J.; Martins, M.; Couto, I.; Fanning, S.; Pages, J. M.; Bolla, J. M.; et al. AcrAB mediated MDR phenotype is maintained after efflux pump genes and their regulators have restored wild type activities. Int. J. Antimicrob. Agents 2009, 34, 602-604.
52. Martins, A.; Spengler, G.; Molnar, J.; Amaral, L. Sequential responses of bacteria to noxious agents (antibiotics) leading to accumulation of mutations and permanent resistance. Biochem. Pharmacol. 2012, 1, doi: 10. 4172/2167-0501. 1000104.
53. Chopra, I.; O'Neill, A. J.; Miller, K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 2003, 6, 137-145.
54. Costa, S. S.; Falcão, C.; Viveiros, M.; Machado, D.; Martins, M.; Melo-Cristino, J.; Amaral, L.; Couto, I. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol. 2011, 11, doi: 10. 1186/1471-2180-11-241.
55. Costa, S. S.; Ntokou, E.; Martins, A.; Viveiros, M.; Pournaras, S.; Couto, I.; Amaral, L. Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone. Int. J. Antimicrob. Agents 2010, 36, 557-561.
56. Spengler, G.; Martins, A.; Schelz, Z.; Rodrigues, L.; Aagaard, L.; Martins, M.; Costa, S. S.; Couto, I.; Viveiros, M.; Fanning, S.; et al. Characterization of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semi-automated ethidium bromide method. In Vivo 2009, 23, 81-87.
57. Viveiros, M.; Martins, M.; Rodrigues, L.; Machado, D.; Couto, I.; Ainsa, J.; Amaral, L. Inhibitors of mycobacterial efflux pumps as potential boosters for TB drugs. Expert Rev. Anti-Infect. Ther. 2012, 10, 983-998.
58. Machado, D.; Couto, I.; Perdigão, J.; Rodrigues, L.; Portugal, I.; Baptista, P.; Veigas, B.; Amaral, L.; Viveiros, M. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 2012, 7, e34538.
59. Rodrigues, L.; Machado, D.; Couto, I.; Amaral, L.; Viveiros, M. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 2012, 12, 695-700.
60. Amaral, L.; Cerca, P.; Spengler, G.; Machado, L.; Couto, I.; Viveiros, M.; Fanning, S.; Pagès, J.-M. Ethidium bromide efflux by salmonella: Modulation by metabolic energy, pH, ions and phenothiazines. Int. J. Antimicrob. Agents 2011, 38, 140-145.
61. Mulkidjanian, A. Y.; Cherepanov, D. A.; Heberle, J.; Junge, W. Proton transfer dynamics at membrane/water interface and mechanism of biological energy conversion. Biochemistry (Moscow) 2005, 70, 251-256.
62. Mulkidjanian, A. Y.; Heberle, J.; Cherepanov, D. A. Protons @ interfaces: Implications for biological energy conversion. Biochim. Biophys. Acta 2006, 1757, 913-930.
63. Varga, Z. G.; Armada, A.; Cerca, P.; Amaral, L.; Mior Ahmad Subki, M. A.; Savka, M. A.; Szegedi, E.; Kawase, M.; Motohashi, N.; Molnár, J. Inhibition of quorum sensing and efflux pump system by trifluoromethyl ketone proton pump inhibitors. In Vivo 2012, 26, 277-285.
64. Ren, J. K.; Petöfi, S.; Molnár, J. Mechanisms of antimotility action of tricyclic compounds in Proteus vulgaris. Acta Microbiol. Hung. 1993, 40, 369-377.
65. Crowle, A. J.; Douvas, G. S.; May, M. H. Chlorpromazine: A drug potentially useful for treating mycobacteria infections. Chemotherapy 1992, 38, 410-419.
66. Amaral, L.; Kristiansen, J. E.; Abebe, L. S.; Millet, W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by Thioridazine: Potential use for the initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother. 1996, 38, 1049-1053.
67. Ordway, D.; Viveiros, M.; Leandro, C.; Amaral, L. Clinical concentrations of Thioridazine kill intracellular Multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2003, 47, 917-922.
68. Martins, M.; Viveiros, M.; Amaral, L. Sila Compound 421, an Inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular XDRTB. Int. J. Antimicrob. Agents 2008, 33, 479-482.
69. Martins, M.; Viveiros, M.; Amaral, L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007, 21, 771-776.
70. van Soolingen, D.; Pando, R. H.; Orozco, H.; Aguilar, D.; Magis, C.; van Ingen, J.; Amaral, L.; Boeree, M. Thioridazine shows promising activity in a murine model of multi-drug resistant tuberculosis. PloS One 2010, 5, e12640.
71. Abbate, E.; Vescovo, M.; Natiello, M.; Cufré, M.; García, A.; Gonzalez Montaner, P.; Ambroggi, M.; Ritacco, V.; van Soolingen, D. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother. 2012, 67, 473-477.
72. Amaral, L. Totally Drug Resistant Tuberculosis can be Treated with Thioridazine in Combination with Antibiotics to which the Patient was Initially Resistant. Biochem. Pharmacol. 2012, doi: 10. 4172/bcpc. 1000e102.
73. Amaral, L.; Viveiros, M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int. J. Antimicrob. Agents 2012, 39, 376-380.
74. Amaral, L.; Molnar, J. Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine. In Vivo 2012, 26, 231-236.
75. Udwadia, Z. F.; Sen, T.; Pinto, L. M. Safety and efficacy of thioridazine as salvagetherapy in Indian patients with XDR-TB. Recent Pat. Antiinfect. Drug Discov. 2011, 6, 88-91.
76. Amaral, L.; Udwadia, Z.; Abbate, E.; van Soolingen, D. The added effect of Thioridazine in treatment of resistant TB. Int. J. Tuberc. Lung Dis. 2012, 16, 1706-1708.
77. Wolfart, K.; Spengler, G.; Kawase, M.; Motohashi, N.; Molnár, J.; Viveiros, M.; Amaral, L. Synergistic interaction between proton pump inhibitors and resistance modifiers: Promoting effects of antibiotics and plasmid curing. In Vivo 2006, 20, 367-372.
78. Spengler, G.; Miczák, A.; Hajdú, E.; Kawase, M.; Amaral, L.; Molnár, J. Enhancement of plasmid curing by 9-aminoacridine and two phenothiazines in the presence of proton pump inhibitor 1-(2-benzoxazolyl)-3, 3, 3-trifluoro-2-propanone. Int. J. Antimicrob. Agents 2003, 22, 223-227.
79. Radhakrishnan, V.; Ganguly, K.; Ganguly, M.; Dastidar, S. G.; Chakrabarty, A. N. Potentiality of tricyclic compound thioridazine as an effective antibacterial and antiplasmid agent. Indian J. Exp. Biol. 1999, 37, 671-675.
80. Evdokimova, O. V.; Smirnov, I. V.; Artem'eva, N. A.; Rozhkova, E. A. Effect of promethazine hydrochloride (pipolphen) on the stability of R plasmid resistance in Escherichia coli (in Russian). Antibiot Khimioter 1997, 42, 8-11.
81. Molnár, J.; Gálfi, M.; Lózsa, A.; Nakamura, M. J. Inhibition of bacterial plasmid replication by stereoselective binding by tricyclic psychopharmacons. Res. Commun. Chem. Pathol. Pharmacol. 1984, 43, 235-249.